Novartis drug shows promise in treating Fragile X syndrome

04/29/2010 | New York Times (tiered subscription model), The

An experimental drug from Novartis caused substantial improvement in behavior in a small study involving adults with Fragile X syndrome, a genetic condition linked to mental disorders such as autism. Dr. Mark C. Fishman, president of the Novartis Institutes for BioMedical Research, said researchers feel "pretty good about the data" but thinks that more clinical trials are necessary to prove effectiveness of the treatment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park